Vistin Pharma ASA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
For the six months, sales was NOK 102.21 million compared to NOK 137.65 million a year ago. Net loss was NOK 14.91 million compared to net income of NOK 16.85 million a year ago. Basic loss per share from continuing operations was NOK 0.34 compared to basic earnings per share from continuing operations of NOK 0.38 a year ago. Diluted loss per share from continuing operations was NOK 0.34 compared to diluted earnings per share from continuing operations of NOK 0.38 a year ago.